[Pentoxifylline and prostaglandins].
Poggesi
L
L
Istituto di Clinica Medica I, Firenze.
Boddi
M
M
Scarti
L
L
Masotti
G
G
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy / Q000378:metabolism; D001792:Blood Platelets / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis; D006801:Humans; D010431:Pentoxifylline / Q000494:pharmacology* / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism*; D013268:Stimulation, Chemical; D013805:Theobromine / Q000031:analogs & derivatives*
D010975:Platelet Aggregation Inhibitors; D011453:Prostaglandins; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D000242:Cyclic AMP; D013805:Theobromine; D010431:Pentoxifylline
Pentossifillina e prostaglandine.